Search the Newsreel

Adaptive Biotechnologies (ADPT) Is Up 10.5% After Raising 2026 MRD Revenue Guidance Has The Bull Case Changed?

AdaptHealth Corp. $AHCO Shares Sold by Reinhart Partners LLC.

Reinhart Partners LLC reduced its stake in AdaptHealth Corp. by 26.4% in the second quarter, selling over 2.6 million shares but still retaining a significant holding. Despite this sale, other institutional investors increased their positions in AHCO. The stock currently holds a "Moderate Buy" …

Renaissance Technologies LLC Acquires Shares of 239,800 Adaptive Biotechnologies Corporation $ADPT

Renaissance Technologies LLC has acquired 239,800 shares of Adaptive Biotechnologies Corporation, valued at approximately $3.33 million, marking a new stake in the company. Institutional investors collectively hold 99.17% of Adaptive Biotechnologies. The company reported better-than-expected quarterly revenue but missed earnings estimates, while analysts maintain …

AHCO Investors Have Opportunity to Join AdaptHealth Corp. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS) is investigating potential securities law violations by AdaptHealth Corp. (NASDAQ: AHCO) on behalf of its investors. This investigation follows AdaptHealth's Q2 2026 financial results, where the company missed earnings estimates and significantly cut its full-year guidance, leading to …

AdaptHealth (AHCO) Reports A Net Loss And Goodwill Impairment, Is The Stock A Bargain?

AdaptHealth Corp. Just Missed Earnings; Here's What Analysts Are Forecasting Now

AdaptHealth Corp. (NASDAQ:AHCO) shares plunged 43% after missing Q2 earnings estimates, with revenues falling 13% short and the company reporting a statutory loss instead of a forecasted profit. Analysts have significantly cut revenue forecasts and now anticipate a loss for 2026, leading to a …

AHCO SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AdaptHealth Corp.

SueWallSt, powered by Levi & Korsinsky LLP, has initiated an investigation into AdaptHealth Corp. (NASDAQ: AHCO) after the company significantly lowered its full-year 2026 revenue and adjusted EBITDA guidance, causing a stock drop of up to 26%. The investigation focuses on whether AdaptHealth made …

AdaptHealth (AHCO) Stock Faces Deeper Doubts After Profit Reset

Adaptive Biotechnologies (ADPT) Stock Gains Little As MRD Growth Meets Wider Losses

Securities Fraud Investigation Into AdaptHealth Corp. (AHCO) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz has announced a securities fraud investigation into AdaptHealth Corp. (AHCO) following a significant drop in its stock price. This investigation comes after AdaptHealth reported a substantial earnings miss and cut its full-year 2026 adjusted EBITDA guidance, citing …

AdaptHealth Corp. Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AdaptHealth Corp. (AHCO)

Levi & Korsinsky is investigating AdaptHealth Corp. (AHCO) after the company significantly cut its full-year 2026 adjusted EBITDA guidance. The reduction from an initial range of $680 million-$730 million to approximately $490 million-$520 million, a drop of $190 million-$210 million, caused a stock decline …

Stocks making big moves yesterday: AdaptHealth, UL Solutions, Ball, Tidewater, and Wayfair

This article highlights several stocks that experienced significant movement yesterday, August 4, 2026, due to their second-quarter earnings reports. AdaptHealth and UL Solutions saw declines after reporting disappointing results, while Ball's strong earnings were overshadowed by profitability concerns. In contrast, Tidewater and Wayfair both …

AdaptHealth Corp. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AHCO)

AdaptHealth Corp. published its Q2 2026 earnings call presentation on August 5, 2026. The company reported an EPS of -$0.07, missing estimates by $0.23, and revenue of $740.31M, down 7.50% year-over-year and missing estimates by $106.47M. This information was shared in conjunction with their …

ADAPTIVE BIOTECHNOLOGIES CORP : PIPER SANDLER RAISES TARGET PRICE TO $27.50 FROM $20.00

Piper Sandler has increased its target price for Adaptive Biotechnologies Corp to $27.50 from $20.00. This adjustment reflects an updated outlook from the analyst firm regarding the company's valuation. The information was reported by Reuters.

Can Danaher (DHR) Trade At A Discount After Its CEO Change?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Danaher stock now sits around US$194.78 after a weak earnings update and a leadership …

AdaptHealth Agrees to Sell Diabetes Business for $235M, Subject to Adjustments

AdaptHealth Corp. announced its second-quarter 2026 financial results, revealing a definitive agreement to sell its Diabetes Health business for $235 million in cash. This divestiture is part of AdaptHealth's strategy to focus on its core Sleep Health, Respiratory Health, and Wellness-at-Home segments. The company …

Adaptive Biotechnologies (NASDAQ: ADPT) raises $345M in 2031 notes

Adaptive Biotechnologies (ADPT) has issued $345 million in 0% convertible senior notes due 2031, using part of the proceeds to repurchase revenue interests and common stock. The company reported a Q2 2026 revenue of $71.6 million, an increase from the previous year, driven by …

AdaptHealth (NASDAQ:AHCO) Releases Quarterly Earnings Results

Adaptive Biotechnologies Corp Q2 2026: Revenue $71.6M, EPS $(0.25) — 10-Q Summary

Adaptive Biotechnologies Corp (ADPT) reported Q2 2026 financial results, with revenue reaching $71.6 million, an increase from $58.9 million in the previous year. The company recorded a net loss of $(39.8) million and a diluted loss per share of $(0.25). Key drivers included a …

AdaptHealth Corp. 2Q 2026: Revenue $740.31M, Net income ($133.93M), EPS ($0.99) — 10-Q Summary

AdaptHealth Corp. reported its second-quarter 2026 results, showing a 12.7% increase in revenue year-over-year to $740.31 million. Despite revenue growth, the company recorded a net loss of $133.93 million and a diluted EPS of ($0.99), a significant decrease compared to the prior year's profit. …

How Investors Are Reacting To Danaher (DHR) CEO Transition, Buybacks, And Updated 2026 Outlook

Danaher Corporation recently reported second-quarter 2026 results showing higher sales and earnings versus a year earlier, confirmed modest third-quarter revenue growth guidance, completed multi-billion-dollar share repurchases, and announced that Executive Vice President Julie Sawyer Montgomery will become President and CEO on October 1, 2026, …

AHCO INVESTOR ALERT: Investigation of AdaptHealth Corp. Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC has announced an investigation into AdaptHealth Corp. (NASDAQ: AHCO) regarding potential violations of federal securities laws. This comes after AdaptHealth revised its financial guidance and reported a decrease in cash flow from operations and negative free cash flow for Q2 …

Investigation launched into AdaptHealth after revised guidance and Q2 cash flow drop. AHCO $6.71 -$4.12 -38.04%

Holzer & Holzer, LLC has launched an investigation into AdaptHealth Corp. following the company's revised financial guidance and second-quarter 2026 results. AdaptHealth reported a decrease in cash flow from operations and a negative free cash flow, attributing the decline to the full-scale launch and …

Danaher Beat Earnings Estimates, so Why Are Investors Still Concerned About Growth?

Danaher Corporation (NYSE:DHR) delivered second-quarter results on July 21, marked by core growth improving compared to the previous quarter, along with disciplined execution that drove high-single-digit adjusted EPS growth. Despite beating earnings estimates, raising its adjusted EPS guidance, and reporting improving trends in its …

Why AdaptHealth (AHCO) Stock Is Trading Lower Today

AdaptHealth Corp. (AHCO) stock significantly dropped by 39.5% after reporting disappointing second-quarter results and drastically cutting its full-year financial guidance. The company posted a loss of $0.99 per share and revenue of $740.3 million, both falling short of analyst expectations, and attributed the lowered …

AdaptHealth lowers outlook as new contract, manufacturer costs pressure margins

AdaptHealth has reduced its full-year financial outlook due to pressures from a new capitated agreement and unexpected manufacturer price increases. Despite a 12.7% increase in second-quarter revenue, implementation costs for a major contract and a $30 million impact from a manufacturer price hike negatively …

AdaptHealth plunges on Q2 results, narrows 2026 revenue guidance

[Computer key - 2nd quarter] jurgenfr * AdaptHealth is down ~42% in Tuesday morning trading after posting Q2 financial results that missed [https://seekingalpha.com/news/4624489-adapthealth-corp-gaap-eps-of-1_07-misses-by-1_22-revenue-of-740_3m-misses-by-106_47m] on both lines and revising its 2026 revenue guidance downwards. * Full-year net revenue is now seen at $2.85B-$2.89B compared to …

AdaptHealth Shares Sink After Earnings Miss and Lower Full-Year Guidance

AdaptHealth (NASDAQ:AHCO) shares plummeted after the company reported second-quarter 2026 results that missed Wall Street expectations and significantly cut its full-year financial outlook. The home medical equipment provider posted a quarterly loss of $0.99 per share and revenue of $740.3 million, both falling short …

Adapthealth Corp stock hits 52-week low at 6.68 USD

Adapthealth Corp (AHCO) stock has reached a 52-week low of $6.68, despite InvestingPro analysis suggesting it may be undervalued and analysts predicting profitability this year with an EPS forecast of $0.94. This low follows disappointing Q2 results where the company missed analyst expectations for …

AdaptHealth Q2 Earnings Call Highlights

This article first appeared on GuruFocus. Release Date: August 04, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Delivered 16% organic growth with record volume gains across the business. Signed a definitive agreement …

AdaptHealth (NASDAQ:AHCO) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 25.7%

AdaptHealth (NASDAQ:AHCO) reported Q2 CY2026 earnings with sales significantly below analyst estimates, leading to a 25.7% stock drop. The company's revenue declined 7.5% year-on-year to $740.3 million, and its full-year revenue guidance of $2.87 billion was substantially lower than analyst expectations. AdaptHealth also posted …

AdaptHealth Q2 revenue rises 12.7% as net loss widens

Goodwill charge, unit sale reshape AdaptHealth Corp. (NASDAQ: AHCO) 2026 view

AdaptHealth Corp. GAAP EPS of -$1.07 misses by $1.22, revenue of $740.3M misses by $106.47M

* AdaptHealth Corp. press release [https://seekingalpha.com/pr/20605287-adapthealth-corp-announces-second-quarter-2026-results] (AHCO [https://seekingalpha.com/symbol/AHCO]): Q2 GAAP EPS of -$1.07 misses by $1.22. * Revenue of $740.3M (+12.7% Y/Y) misses by $106.47M. * Organic revenue growth of 15.9%, with growth across each of the Company’s reportable segments. * Grew registered myAPP …

Danaher promotes Julie Sawyer Montgomery to CEO

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Name: Julie Sawyer Montgomery New title: CEO, Danaher Previous title: Executive vice president, diagnostics, Danaher Danaher has named Julie Sawyer Montgomery as …

Adaptive Biotechnologies CCO Susan Bobulsky sells $31,176 shares

Susan Bobulsky, CCO of Adaptive Biotechnologies (NASDAQ:ADPT), sold